Direkt zum Inhalt

Numab Therapeutics

Industry:
Immuno-Oncology and Inflammation
Company status:
Private

Numab applies its proprietary antibody discovery and engineering technology to generate highly potent and stable antibody Fv fragments, which serve as building blocks to create mono- or multispecific antibody fragment-based therapeutics with tailored pharmacokinetic properties.
The company has created a broad proprietary pipeline of compounds in immune-oncology and the field of inflammation and has entered into several partnerships with pharmaceutical companies.

Zurück